Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
Abstract Background The current study aimed to evaluate growth and neurodevelopmental status in patients with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB). Methods This historical cohort study was conducted on neonates with ROP who were treated with IVB and age and bi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-11-01
|
| Series: | International Journal of Retina and Vitreous |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40942-021-00340-6 |
| _version_ | 1828960309531901952 |
|---|---|
| author | Majid Abrishami Hassan Boskabadi Mojtaba Abrishami Farid Shekarchian Majid Khadem-Rezaiyan Nasser Shoeibi |
| author_facet | Majid Abrishami Hassan Boskabadi Mojtaba Abrishami Farid Shekarchian Majid Khadem-Rezaiyan Nasser Shoeibi |
| author_sort | Majid Abrishami |
| collection | DOAJ |
| description | Abstract Background The current study aimed to evaluate growth and neurodevelopmental status in patients with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB). Methods This historical cohort study was conducted on neonates with ROP who were treated with IVB and age and birth weight-matched controls who did not need IVB. Apgar score less than five, history of blood transfusion and history of infectious diseases were among exclusion criteria. Indirect ophthalmoscopic examinations were performed till complete retinal vascularization. Growth and neurodevelopmental status were evaluated by Age and Stages Questionnaire (ASQ) at the ages of 6, 12, and 18 months. Developmental milestones were assessed in five areas (gross motor, fine motor, personal-social status, problem-solving, and relationship) and overall issues. Results A total of 34 cases and 36 controls were included in the present study. Birth weight and corrected gestational age were not statistically different between the groups. In a follow-up period of 18 months, bevacizumab was effective as a primary treatment in the treatment of severe cases of ROP. There was no significant difference between the two groups regarding the five areas and overall issues in follow-up intervals (P > 0.05). Conclusions The obtained results did not show any growth and neurodevelopmental differences between treatment-naïve infants and those receiving IVB for the treatment of ROP. |
| first_indexed | 2024-12-14T09:24:57Z |
| format | Article |
| id | doaj.art-0d3a9cf2371a456f83ee93a4d6ca78bc |
| institution | Directory Open Access Journal |
| issn | 2056-9920 |
| language | English |
| last_indexed | 2024-12-14T09:24:57Z |
| publishDate | 2021-11-01 |
| publisher | BMC |
| record_format | Article |
| series | International Journal of Retina and Vitreous |
| spelling | doaj.art-0d3a9cf2371a456f83ee93a4d6ca78bc2022-12-21T23:08:13ZengBMCInternational Journal of Retina and Vitreous2056-99202021-11-01711610.1186/s40942-021-00340-6Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control studyMajid Abrishami0Hassan Boskabadi1Mojtaba Abrishami2Farid Shekarchian3Majid Khadem-Rezaiyan4Nasser Shoeibi5Eye Research Center, Mashhad University of Medical SciencesNeonatal Research Center, Mashhad University of Medical SciencesEye Research Center, Mashhad University of Medical SciencesEye Research Center, Mashhad University of Medical SciencesClinical Research Development Unit, Mashhad University of Medical SciencesEye Research Center, Mashhad University of Medical SciencesAbstract Background The current study aimed to evaluate growth and neurodevelopmental status in patients with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB). Methods This historical cohort study was conducted on neonates with ROP who were treated with IVB and age and birth weight-matched controls who did not need IVB. Apgar score less than five, history of blood transfusion and history of infectious diseases were among exclusion criteria. Indirect ophthalmoscopic examinations were performed till complete retinal vascularization. Growth and neurodevelopmental status were evaluated by Age and Stages Questionnaire (ASQ) at the ages of 6, 12, and 18 months. Developmental milestones were assessed in five areas (gross motor, fine motor, personal-social status, problem-solving, and relationship) and overall issues. Results A total of 34 cases and 36 controls were included in the present study. Birth weight and corrected gestational age were not statistically different between the groups. In a follow-up period of 18 months, bevacizumab was effective as a primary treatment in the treatment of severe cases of ROP. There was no significant difference between the two groups regarding the five areas and overall issues in follow-up intervals (P > 0.05). Conclusions The obtained results did not show any growth and neurodevelopmental differences between treatment-naïve infants and those receiving IVB for the treatment of ROP.https://doi.org/10.1186/s40942-021-00340-6Retinopathy of prematurityGrowthNeurodevelopmental statusBevacizumabRetina |
| spellingShingle | Majid Abrishami Hassan Boskabadi Mojtaba Abrishami Farid Shekarchian Majid Khadem-Rezaiyan Nasser Shoeibi Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study International Journal of Retina and Vitreous Retinopathy of prematurity Growth Neurodevelopmental status Bevacizumab Retina |
| title | Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study |
| title_full | Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study |
| title_fullStr | Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study |
| title_full_unstemmed | Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study |
| title_short | Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study |
| title_sort | growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab a case control study |
| topic | Retinopathy of prematurity Growth Neurodevelopmental status Bevacizumab Retina |
| url | https://doi.org/10.1186/s40942-021-00340-6 |
| work_keys_str_mv | AT majidabrishami growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT hassanboskabadi growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT mojtabaabrishami growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT faridshekarchian growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT majidkhademrezaiyan growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT nassershoeibi growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy |